361 related articles for article (PubMed ID: 25678771)
1. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
Szumowski JD; Lynch JB
Drug Des Devel Ther; 2015; 9():677-82. PubMed ID: 25678771
[TBL] [Abstract][Full Text] [Related]
2. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
3. Delamanid for multidrug-resistant pulmonary tuberculosis.
Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
[TBL] [Abstract][Full Text] [Related]
4. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
5. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
6. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
Blair HA; Scott LJ
Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
[TBL] [Abstract][Full Text] [Related]
7. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
[No Abstract] [Full Text] [Related]
8. Bedaquiline and delamanid in tuberculosis.
Esposito S; Bianchini S; Blasi F
Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
[TBL] [Abstract][Full Text] [Related]
9. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
Thakare R; Soni I; Dasgupta A; Chopra S
Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
[TBL] [Abstract][Full Text] [Related]
10. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
[TBL] [Abstract][Full Text] [Related]
12. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
Hu M; Zheng C; Gao F
Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Subay S; Adiono SH
Int J Mycobacteriol; 2024 Apr; 13(2):140-146. PubMed ID: 38916383
[TBL] [Abstract][Full Text] [Related]
15. Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis.
Prescrire Int; 2017 Apr; 26(181):89-92. PubMed ID: 30730656
[No Abstract] [Full Text] [Related]
16. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
17. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
[TBL] [Abstract][Full Text] [Related]
18. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
[No Abstract] [Full Text] [Related]
19. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
[TBL] [Abstract][Full Text] [Related]
20. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis.
Bhatnagar AK; Hemanthkumar AK; Muthu Vijayalakshmi M; Vohra V; Padmapriyadarsini C; Ramesh PM; Taneja G; Chavan VN; Jeyadeepa B; Bhui NK; Solanki R
Ther Drug Monit; 2024 Jun; 46(3):363-369. PubMed ID: 38161267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
